First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and
PhysioMimix® Multi-Organ Microphysiological System selected by The Scientist as a ‘Top 10 Innovation 2021′
Next generation Organ-on-a-Chip technology listed second in Top 10 Innovations for 2021 System enables pre-clinical studies that simulate complex
CN Bio and iiCON announce COVID-19 research collaboration
Partnership focused on validation of novel Organ-on-a-Chip infection models Human-relevant single and multi-organ SARS-CoV-2 infected models
CN Bio expands service offering to support oncology drug discovery
New Oncology Service supports unique in vitro investigations into the PK/PD relationship Harnesses CN Bio’s proprietary PhysioMimix® PK system
CN Bio licenses human gut organ microbiome modelling tool from MIT and Northeastern University
Enables accurate modelling of the human colon and the mucosal barrier Provides new insights to the relationship between human microbiome and effect
Lonza and CN Bio announce distribution agreement
Lonza and CN Bio announce distribution agreement providing pre-validated hepatocytes for use on innovative Organ-on-a-chip range Through a new
CN Bio’s PhysioMimix® adopted by King’s College London to investigate chronic liver disease
Next generation organ-on-a-chip (OOC) technology to be used to investigate the human gut microbiome for improving outcomes for patients with liver
CN Bio FDA collaboration expanded
The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications Extension aims to
Introducing the PhysioMimix® OOC Multi-Organ Microphysiological System
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the